Logo

RAPP

Rapport Therapeutics, Inc. Common Stock

RAPP

Rapport Therapeutics, Inc. Common Stock • NASDAQ
$29.71 ▲ 0.95% (+0.28)
Market Cap $1.08 B
52w High $42.27
52w Low $6.43
Dividend Yield 0%
P/E -13.09
Volume 281.95K
Outstanding Shares 36.50M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $29.986M ▲ $-26.925M ▼ 0% $-0.71 ▲ $-26.669M ▲
Q2-2025 $0 $29.496M ▲ $-26.732M ▼ 0% $-0.75 ▼ $-29.244M ▼
Q1-2025 $0 $27.108M ▲ $-24.063M ▼ 0% $-0.12 ▼ $-26.864M ▼
Q4-2024 $0 $23.521M ▲ $-19.98M ▼ 0% $-0.1 ▼ $-23.261M ▼
Q3-2024 $0 $21.64M $-17.537M 0% $-0.091 $-21.421M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $513.026M ▲ $535.323M ▲ $23.706M ▲ $511.617M ▲
Q2-2025 $260.447M ▼ $285.495M ▼ $21.983M ▲ $263.512M ▼
Q1-2025 $285.382M ▼ $302.053M ▼ $16.217M ▲ $285.836M ▼
Q4-2024 $305.28M ▼ $314.933M ▼ $9.506M ▲ $305.427M ▼
Q3-2024 $320.661M $331.144M $8.03M $323.114M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-26.925M ▼ $-17.465M ▲ $-56.776M ▼ $270.533M ▲ $196.292M ▲ $-17.599M ▲
Q2-2025 $-26.732M ▼ $-25.07M ▼ $22.596M ▲ $-63K ▼ $-2.537M ▼ $-25.092M ▼
Q1-2025 $-24.063M ▼ $-20.237M ▼ $21.031M ▼ $5K ▼ $799K ▼ $-20.528M ▼
Q4-2024 $-19.98M ▼ $-14.446M ▲ $31.93M ▲ $7K ▲ $17.491M ▲ $-14.672M ▲
Q3-2024 $-17.537M $-16.415M $-53.041M $-1.394M $-70.85M $-16.555M

Five-Year Company Overview

Income Statement

Income Statement Rapport is still a pure research‑stage biotech, so it has no product revenue yet. The income statement is dominated by research and operating costs, which have been rising as the company ramps up clinical work and builds out its organization. Losses are growing, which is normal for a young drug developer investing heavily in trials and platform development. The key point: this is a story of spending now in hopes of future therapies, not one of current earnings or profitability.

Balance Sheet

Balance Sheet The balance sheet shows a company that has been steadily building its asset base and shareholder equity as it raises capital, with essentially no reliance on debt recently. Cash is a key asset, and while it has fluctuated, overall financial resources have grown as the company has scaled up. The absence of meaningful debt reduces financial strain, but the balance sheet still reflects a business that will depend on future funding rounds or partnerships until it can generate its own revenue.

Cash Flow

Cash Flow Cash flows are negative from operations, reflecting ongoing research, clinical trials, and corporate build‑out, with no offsetting product sales. Free cash flow is also negative, but capital spending on equipment and facilities appears modest, so most cash use is tied directly to running and expanding the R&D engine. This pattern is typical for an early‑stage biotech: the main financial risk is how long existing cash can support the current pace of development before new funding is needed.

Competitive Edge

Competitive Edge Rapport is trying to carve out a differentiated position in neuroscience by using its RAP platform to design highly targeted drugs for brain and nervous system disorders. This specificity could offer better effectiveness with fewer side effects compared with traditional, broadly acting CNS drugs. Its lead program in drug‑resistant epilepsy and related conditions targets areas of high unmet need, which can be attractive if the science pans out. The company’s moat rests on proprietary biology, specialized know‑how, and intellectual property, but it still competes in a crowded space with larger, well‑funded pharma and biotech companies and faces the usual clinical and regulatory hurdles, including trial design and FDA feedback.

Innovation and R&D

Innovation and R&D Innovation is the core of Rapport’s story. The RAP platform is designed to find and drug receptor‑associated proteins that control where and how brain receptors function, enabling more precise targeting of disease‑related circuits. The lead candidate, RAP‑219, is being developed for focal epilepsy and other CNS conditions, with additional early programs in chronic pain and hearing disorders. The company has already encountered at least one regulatory speed bump with an FDA hold that required protocol changes, underscoring the complexity and uncertainty of CNS drug development. R&D is highly focused and science‑driven, with meaningful upside if the platform is validated in the clinic, but the pipeline is still relatively concentrated around a small number of key assets, which increases program‑specific risk.

Summary

Rapport Therapeutics is an early‑stage biotech focused on precision neuroscience, with no revenue yet and a financial profile typical of a clinical‑stage company: rising R&D spending, widening losses, negative cash flow, and a growing asset and equity base funded mainly by shareholders rather than lenders. Its investment case hinges almost entirely on the success of its RAP technology platform and lead drug candidate, aiming to deliver more targeted treatments for serious CNS conditions. The company appears to have a potentially meaningful scientific edge and a clear focus on high‑need patient populations, but it is still in the validation phase, faces normal but significant clinical and regulatory risks, and will likely remain dependent on external financing or partnerships until it can bring a product to market.

NEWS

November 25, 2025 · 7:00 AM UTC

Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting

Read more

November 6, 2025 · 7:00 AM UTC

Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update

Read more

November 5, 2025 · 4:05 PM UTC

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Read more

October 7, 2025 · 9:03 AM UTC

Rapport Acquires Aquifer Motion, Becoming the First Company to Offer Real-Time, AI-Powered Avatars with Full-Body Animation

Read more

September 12, 2025 · 5:11 AM UTC

Crédit Agricole Normandie Seine : Rapport financier semestriel 06 2025

Read more